Fusion Pharmaceuticals CEO John Valliant's 2022 pay slips 16% to $2.7M
Fusion Pharmaceuticals reports 2022 executive compensation
By ExecPay News
Published: April 27, 2023
Fusion Pharmaceuticals reported fiscal year 2022 executive compensation information on April 27, 2023.
In 2022, three executives at Fusion Pharmaceuticals received on average a compensation package of $1.9M, a 29% decrease compared to previous year.
Average pay of disclosed executives at Fusion Pharmaceuticals
John Valliant, Chief Executive Officer, received $2.7M in total, which decreased by 16% compared to 2021. 69% of Valliant's compensation, or $1.9M, was in option awards. Valliant also received $238K in non-equity incentive plan, $595K in salary, as well as $31K in other compensation.
John Crowley, Chief Financial Officer, received a compensation package of $1.4M, which decreased by 11% compared to previous year. 54% of the compensation package, or $773K, was in option awards.
Eric Burak, Chief Technology Officer, earned $1.4M in 2022, a 52% decrease compared to previous year.
Related executives
You may also like
Source: SEC filing on April 27, 2023.